Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT01309672
- Locations
- 🇺🇸
Grant Medical Center Cancer Care, Columbus, Ohio, United States
🇺🇸Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸Kaiser Permanente Medical Center - Richmond, Richmond, California, United States
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
- Conditions
- Interventions
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 190
- Registration Number
- NCT01254864
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Abiraterone Post Ketoconazole for Prostate Cancer
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2018-01-08
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 42
- Registration Number
- NCT01199146
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Cougar Biotechnology, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT01088529
Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 24
- Registration Number
- NCT01023061
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸MultiCare Regional Cancer Center - Tacoma, Tacoma, Washington, United States
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01017939
- Locations
- 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇨🇦BC Cancer Agency, Vancouver, British Columbia, Canada
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 58
- Registration Number
- NCT00924469
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT00910754
- Locations
- 🇨🇦
BC Cancer Agency-Vancouver, Vancouver, British Columbia, Canada
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1088
- Registration Number
- NCT00887198
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.